Mobile Phone Apps for Quality of Life and Well-Being Assessment in Breast and Prostate Cancer Patients: Systematic Review by Rincón, Esther et al.
Review
Mobile Phone Apps for Quality of Life and Well-Being Assessment
in Breast and Prostate Cancer Patients: Systematic Review
Esther Rincon1*, PhD; Francisco Monteiro-Guerra2*, MS; Octavio Rivera-Romero3, PhD; Enrique Dorronzoro-Zubiete3,
PhD; Carlos Luis Sanchez-Bocanegra4, PhD; Elia Gabarron5, PhD
1Department of Psychology and Pedagogy, Universidad San Pablo Centro de Estudios Universitarios, Alcorcón (Madrid), Spain
2Salumedia Tecnologias, Seville, Spain
3Department of Electronic Technology, Universidad de Sevilla, Seville, Spain
4Department of Architecture and Computer Technology, Universidad de Sevilla, Seville, Spain
5Norwegian Centre for eHealth Research, University Hospital of North Norway, Tromsø, Norway
*these authors contributed equally
Corresponding Author:
Esther Rincon, PhD
Department of Psychology and Pedagogy
Universidad San Pablo Centro de Estudios Universitarios
Campus de Montepríncipe, Urbanización Montepríncipe, Pabellón MED, Despacho 0022
Alcorcón (Madrid), 28925
Spain
Phone: 34 913 724 700 ext 4609
Fax: 34 913 724 700
Email: maria.rinconfernande@ceu.es
Abstract
Background: Mobile phone health apps are increasingly gaining attention in oncological care as potential tools for supporting
cancer patients. Although the number of publications and health apps focusing on cancer is increasing, there are still few specifically
designed for the most prevalent cancers diagnosed: breast and prostate cancers. There is a need to review the effect of these apps
on breast and prostate cancer patients’ quality of life (QoL) and well-being.
Objective: The purposes of this study were to review the scientific literature on mobile phone apps targeting breast or prostate
cancer patients and involving QoL and well-being (anxiety and depression symptoms) and analyze the clinical and technological
characteristics, strengths, and weaknesses of these apps, as well as patients’ user experience with them.
Methods: We conducted a systematic review of peer-reviewed literature from The Cochrane Library, Excerpta Medica Database,
PsycINFO, PubMed, Scopus, and MEDLINE to identify studies involving apps focused on breast and/or prostate cancer patients
and QoL and/or well-being published between January 1, 2000, and July 12, 2017. Only trial studies which met the inclusion
criteria were selected. The systematic review was completed with a critical analysis of the apps previously identified in the health
literature research that were available from the official app stores.
Results: The systematic review of the literature yielded 3862 articles. After removal of duplicates, 3229 remained and were
evaluated on the basis of title and abstract. Of these, 3211 were discarded as not meeting the inclusion criteria, and 18 records
were selected for full text screening. Finally, 5 citations were included in this review, with a total of 644 patients, mean age 52.16
years. Four studies targeted breast cancer patients and 1 focused on prostate cancer patients. Four studies referred to apps that
assessed QoL. Only 1 among the 5 analyzed apps was available from the official app store. In 3 studies, an app-related intervention
was carried out, and 2 of them reported an improvement on QoL. The lengths of the app-related interventions varied from 4 to
12 weeks. Because 2 of the studies only tracked use of the app, no effect on QoL or well-being was found.
Conclusions: Despite the existence of hundreds of studies involving cancer-focused mobile phone apps, there is a lack of
rigorous trials regarding the QoL and/or well-being assessment in breast and/or prostate cancer patients. A strong and collective
effort should be made by all health care providers to determine those cancer-focused apps that effectively represent useful,
accurate, and reliable tools for cancer patients’ disease management.
Trial Registration: PROSPERO CRD42017073069; https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=
CRD42017073069 (Archived by WebCite at http://www.webcitation.org/6v38Clb9T)
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Introduction
The number of new cancer cases diagnosed every year
worldwide is rapidly rising from 14.1 million in 2012 to well
over 20 million predicted by 2030 [1]. Of those, breast and
prostate cancers are the most prevalent diagnosed in women
and men, respectively [1]. It should be noted that around 30%
to 40% of these cancer patients suffer from psychological
distress (anxiety and depression symptoms commonly reported)
as has been mentioned previously by a meta-analysis comprising
94 studies and 14,078 cancer patients [2]. This emotional distress
has been associated with poorer quality of life (QoL) [3].
Well-being, QoL, and treatment satisfaction in breast and
prostate cancer patients could be monitored by ubiquitous
technologies such as mobile phone health apps, which can
provide useful data to reflect on therapy work [4] and thereby
improve patients’ well-being.
Mobile phone health apps have the potential to revolutionize
psychological science because they can collect behavioral data
[5] and behavioral information with great ecological validity
[6], facilitating high-frequency assessments and more objective
data collection [7]. These apps can also potentially
empower patients, promoting behavior changes, facilitating
self-monitoring of symptoms [8], improving their educational
level [9], and allowing patients the feeling of being in contact
with their health care team [10].
Apps are widely used by professionals and patients, and attention
to them in health care environments is increasing daily [9].
However, there are some important concerns about their use.
Because of the large number of health care apps available,
patients could get overwhelmed, encountering difficulties in
finding the right app or features [11]. Poorly validated
information, often created by nonexperts [12], and a lack of
updated data [13] have also been mentioned as concerning issues
related to health apps. Limited evidence involving these apps
in studies [14] and little or no quality control or regulations to
guarantee the apps as user-friendly, accurate, or efficacious
tools [15] have also been reported.
In several systematic reviews on mobile phone health apps,
authors urge different strategies that will result in higher quality
evidence for app effectiveness and contents [8,13,16-20]. This
would allow us to distinguish apps that subscribe to
evidence-based protocols from those that do not [21]. The health
care team should have a leading role not only in the review and
verification of app contents but also in determining the most
reliable ones and in selecting the patients best suited to using
them [13]. Therefore, health care providers and organizations
should standardize the identification, evaluation, and selection
of these mobile health (mHealth) apps to maximize their utility
and safety [15].
Attending to patients’ point of view about using mHealth apps,
authors have commonly used survey studies to determine the
user experience. In general, cancer patients positively value the
use of Internet-based technologies for health care management
and feel comfortable using them [22]. Breast cancer patients
usually use this technology to seek general information, search
for therapies or scientific data, and exchange information with
other patients [23]. Authors have also pointed out the importance
of including customizable functionalities in mobile phone apps
in order to manage care-related information so that these features
can be easily modified depending on changes in the user’s needs
[24]. Other people affected by cancer, such as prostate cancer
patients, have shown interest in using apps, indicating apps
should be easy to use, tailored to the individual, and include
social support [25]. A recent survey of 375 cancer patients
reported that about half of the patients (182/375, 48.5%) were
willing to send data via an app supporting their oncological
treatment and follow-up [4]. Moreover, around two-thirds
(125/182, 68.7%) agreed to use these regularly sent data as an
ideal complement to the standard follow-up. The most
mentioned characteristics that should be included in a
cancer-focused app were pseudonymizing, data protection, and
feedback from a physician based on the patients’ input [4].
Although mHealth apps could be useful tools for cancer patients
[26], there are only a few apps focused on oncological care that
support patients during treatment and aftercare [4]. The purposes
of this study were to (1) identify evidence-based mobile phone
health apps focused on QoL and well-being (anxiety and
depression symptoms) in breast and/or prostate cancer patients,
(2) recognize their clinical and technological characteristics,
(3) categorize their clinical and technological strengths and
weaknesses, and (4) determine patients’ user experience
(satisfaction level and comments regarding the apps used).
Methods
Overview
We developed a systematic search strategy to detect all relevant
studies involving the use of mobile phone apps for QoL and/or
well-being (anxiety and depression symptoms) in breast and/or
prostate cancer on July 12, 2017. Once we determined these
studies, we searched the identified apps on the online market
to describe them. The systematic research protocol is registered
at PROSPERO [CRD42017073069].
Reviewing the Scientific Literature
Selection Criteria
Articles were considered potentially relevant if they were trials
or peer-reviewed studies published between January 1, 2000,
and July 12, 2017, including a smartphone app focused on QoL
and/or well-being (anxiety and depression symptoms) used by
breast and/or prostate cancer patients.
We considered a smartphone “a mobile phone with Internet
connectivity and the ability to download and run third-party
software apps available from a commercial marketplace” [27].
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We excluded articles that did not involve a mobile phone app
(eg, a Web-based or iPad app), medical studies, systematic
reviews and meta-analyses, abstracts or congress papers,
qualitative studies, study protocols, and studies not including
QoL or well-being assessment. We applied no language
restrictions.
The search strategy followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines
[28]. We searched for trials in The Cochrane Library, Excerpta
Medica Database (EMBASE), PsycINFO (via ProQuest),
PubMed, Scopus, and MEDLINE (via OvidSP) on July 12,
2017. We extracted trials with the keywords “breast cancer +
app,” “breast cancer + mHealth,” “breast cancer + mobile
application,” “prostate cancer + app,” “prostate cancer +
mHealth,” and “prostate cancer + mobile application” published
between January 1, 2000, and July 12, 2017. Two of the authors
of this study (ER and EG) independently reviewed the titles and
abstracts of the total search yield to identify eligible articles.
The full text of the article was retrieved if any reviewer
considered a citation potentially relevant. In case of
disagreement, a third reviewer (FG) selected the reference finally
included, based on inclusion and exclusion criteria. Search
results were stored using Endnote version X8 (Clarivate
Analytics). Duplications of studies were removed.
Data Extraction
Two of the authors of this study (ER and EG) independently
reviewed the full text of the articles meeting the eligibility
criteria. The interrater agreement (kappa value) was calculated
with SPSS version 22 (IBM Corp). The following data were
extracted from the selected papers: (1) general patient and study
characteristics (year of publication, country of study, language,
author affiliations, number of participants, mean age, and cancer
type targeted), (2) clinical characteristics (QoL assessment,
other variables measured, functionalities, type of validated
questionnaire involved and timing for assessment, treatment
offered, main clinical results, quality of the study, randomized
controlled trial [RCT] design, social media inclusion, theoretical
framework based, and quality of the journal), (3) clinical
strengths and weaknesses, and (4) patients’ user experience
(satisfaction level and comments regarding the apps used).
Disagreements were rare and were easily resolved by consensus.
Two of the authors (ORR and ED) independently reviewed the
full text of selected articles and extracted the following
information: (1) technological characteristics (app name,
platform, availability in markets, price, number of downloads,
rating, patients targeted, and main features), (2) technological
strengths and weaknesses, and (3) patients’ user experience
(ratings, health certification obtained, and number of user
comments). Disagreements were resolved by a third reviewer
(FG). The quality of the included studies was assessed in terms
of their design. Nonrandomized, observational, descriptive, and
qualitative studies were considered low to medium quality.
Quasi-randomized and interventional studies and studies with
strongest design were considered of moderate to high quality.
Reviewing the Apps on the Market
In addition to the systematic review, 3 of the authors (ORR,
ED, and CSB) downloaded the apps identified in the studies
from the online store. They collected the following information:
(1) technological characteristics, (2) technological strengths and
weaknesses, and (3) patients’ user experience (satisfaction level
and comments regarding the app used). An English language
restriction was applied for the mobile phone apps downloaded.
Results
General Characteristics
The search of the electronic databases retrieved 3862 citations.
After removal of duplicates, 3229 remained and were evaluated
on the basis of title and abstract. Of these, 3211 were discarded
because they clearly did not meet the inclusion criteria. Based
on titles and abstracts, 18 records were selected for full text
screening; 13 out of these 18 [29-41] being discarded for various
reasons (see Multimedia Appendix 1). A total of 5 publications
[42-46] were finally included. An interrater agreement of
kappa=.561 was found, reaching a moderate agreement
according to Landis and Koch [47]. All chosen studies were
deemed to be of sufficient quality to contribute equally to the
thematic synthesis. A PRISMA flowchart is shown in Figure 1
[28].
The 5 studies included a total of 644 patients, mean age 52.16
years (sample sizes and mean ages listed in Table 1). Of these,
3 studies were conducted in Korea [42,44,46], 1 in the United
States [43], and 1 in Sweden [45]. All main authors affiliations
were university departments [42-46]. The majority of the studies
targeted breast cancer patients [42-44,46]; only 1 focused on
prostate cancer patients [45]. Other general characteristics of
the studies included are summarized in Table 1.
Clinical and Technological Characteristics
Regarding the clinical approach, 4 of the 5 included studies
referred to apps that assessed QoL [43-46]. Among the other
variables measured were depression status (mood, anxiety, and
sleep satisfaction) [42]; daily food intake, daily exercise, daily
body weight, weight efficacy, anthropometrics, and physical
activity [43]; sleep disturbance [44]; sense of coherence, bladder
and bowel function, fatigue, pain, anxiety, distress, sleep, and
flushing [45]; physical activity [43,46]; and user satisfaction
[46].
All studies allowed patients to collect patient-reported outcome
measures [42-46], and 3 included a related-intervention app
[43,45,46].
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Figure 1. Systematic review of the literature flowchart.
Table 1. General characteristics of included studies (n=5).
Cancer typeMean ageParticipant numberCountry/languagePublication yearStudy
Breast44.3578Korea/Korean2016Kim et al [42]
Breast58.4 50United States/English2015McCarroll et al [43]
Breast4530Korea/Korean2014Min et al [44]
Prostate69130Sweden/Swedish2017Sundberg et al [45]
Breast50.3356Korea/Korean2017Uhm et al [46]
The included studies measured QoL through different
questionnaires such as the Functional Assessment of Cancer
Therapy–General (FACT-G) [48], a generic core questionnaire
that comprises 27 items divided into 4 domains (physical,
functional, emotional, and social well-being) [49]; the EuroQol
5 Dimensional Questionnaire (EQ-5D-3L) [50], a generic health
outcome instrument comprising 5 dimensions (mobility,
self-care, usual activities, pain/discomfort, and
anxiety/depression) [49]; the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire–Core (EORTC QLQ-C30) [51], a 30-item generic
cancer questionnaire that consists of 5 function scales (physical,
role, emotional, cognitive, and social), a global health scale, 3
multi-item symptom scales (fatigue, nausea/vomiting, and pain),
and 6 single item scales (dyspnea, sleep, appetite, constipation,
diarrhea, and financial difficulties due to disease) [49]; and the
EORTC complementary modules on prostate cancer, QLQ-PR25
[52], and breast cancer, QLQ-BR23 [53]. One study did not
assess QoL symptoms [42], focusing only on well-being
assessment through the Patient Health Questionnaire (PHQ-9)
[54], which measures both the presence and the severity of 9
depression symptoms and is able to yield a diagnosis [55]. Only
one of the included studies reported the theoretical framework
on which the app relied. Further details on other clinical
variables assessed by the included studies are reported in Table
2.
Concerning the main clinical results, the adherence to the
self-reporting measures was associated with higher accuracy of
depression screening [42]. Moreover, the compliance with the
daily self-reporting rates was not affected by depression
symptoms or health-related quality of life (HRQoL) status
reported by the patients [44]. Of the 3 studies that included
intervention [43,45,46], only 2 reported a QoL improvement
[45,46]. The real-time assessment and management of symptoms
through Interaktor [45] produced significantly less burden in
emotional functioning, insomnia, and urinary-related symptoms
at T2 (after end of treatment, which ranged from 5 to 8 weeks)
and at T3 (3 months after end of treatment) compared with the
control group. Likewise, the 12-week regimen of aerobic and
resistance exercise through Smart After Care [46] produced a
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significant improvement in physical function, physical activity,
and QoL at baseline and 12 weeks. The 4-week comprehensive
lifestyle program focusing on nutrition quality, physical activity,
and improving eating displayed by LoseIt! [43] did not affect
QoL.
With regard to the quality of the studies, 3 were considered of
low-to-medium level [42,43,44], and 2 a medium-to-high level
of quality [45,46].
The study design involved 2 prospective, nonrandomized
multicenter controlled trials [45,46], 1 with control group [45],
but no RCT designs were included. None of the 5 studies
involved social media features, and only 1 study [43] mentioned
the theoretical framework, social cognitive theory, on which it
was based.
Concerning the publication journals, 4 out of the 5 included
studies [42,43,45,46] were published in the last 3 years
(2015-2017). Scientific journals are ranked yearly based on
impact factor data, and the Journal Citation Reports (JCR)
published by Clarivate Analytics are widely used as a quality
indicator. The JCR ranks journals into categories based on which
quartile of the impact factor distribution the journal occupies
for that category: Q1 represents the top 25% of journals in the
distribution, Q2 between the top 50% and top 25% of journals,
and Q3 between the top 75% and top 50% of journals. According
to the 2017 JCR, 4 studies [42-44,46] were issued in journals
ranking Q1 or Q2.
With regard to technological characteristics, all of the 5 studies
included provided the names of the mobile phone apps evaluated
[42-46]. There were 2 studies involving the same app [42,44]
(see Table 3). The majority of the studies included an app
targeted at cancer patients [42,44-46]. The main features of the
apps were focused on exercise and nutrition logging [43];
collection of patient-reported outcomes [44]; early detection,
reporting, and management of symptoms [45]; and exercise by
a step counter [46]. More technological characteristics can be
seen in Table 3.
App functionalities included the following: (1) customization
and personalization features (create a menu plan and calorie
tracker [43] to establish an individual profile), (2) motivational
features (providing feedback), and (3) social features
(developing a community for inspiration).
Table 2. Clinical characteristics of included studies (n=5).
Quality of studyTreatment
offered
Validated questionnaire/timingFunctionalitiesQoLa
assessment
Study
Low-mediumNoPHQ-9c via app biweeklyPROb: daily mental health ratings
over a 48-week period
NoKim et al [42]
Low-mediumComprehensive
lifestyle pro-
gram
FACT-Gd, WELe at baseline and at
4-week follow-up
PRO: daily, real-time, and motiva-
tional feedback + intervention
YesMcCarroll et al [43]
Low-mediumNoBDIf, EQ-5D-3Lg via app on a daily
basis for 90 days
PRO: daily basis over a 90-day peri-
od
YesMin et al [44]
Medium-highManagement of
symptoms
EORTC QLQ-C30i, EORTC QLQ-
PR25j via app daily at any time
during radiotherapy and 3 weeks
after completion
PRO: daily, real-time assessment of
symptoms and concerns during ra-
diotherapy + interventionh
YesSundberg et al [45]
Medium-high12-week regi-
men of aerobics
EORTC QLQ-C30, EORTC QLQ-
BR23k at baseline and 12 weeks
PRO + interventionhYesUhm et al [46]
aQoL: quality of life.
bPRO: patient-reported outcome measures.
cPHQ-9: Patient Health Questionnaire–9.
dFACT-G: Functional Assessment of Cancer Therapy–General.
eWEL: Weight Efficacy Lifestyle questionnaire.
fBDI: Beck Depression Inventory.
gEQ-5D-3L: EuroQol 5-Dimension 3-Level survey.
hSignificant improvement in quality of life.
iEORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core.
jEORTC QLQ-PR25: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Prostate.
kEORTC QLQ-BR23: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Breast Cancer.
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Table 3. Technological characteristics of included studies (n=5).
Patients
Targeted
RatingsDownloadsPriceAvailable in
markets
PlatformApp nameStudy
YesUnknownUnknownUnknownNoAndroid/iOSPit-a-PatKim et al [42]
NoAndroid: 4.4;
iOS: 4.0
Android:
5,000,000-
10,000,000
free/premiumYesAndroid/iOSLoseIt!McCarroll et al [43]
YesUnknownUnknownUnknownNoAndroid/iOSPit-a-PatMin et al [44]
YesUnknownUnknownUnknownNoUnknownInteraktorSundberg et al [45]
YesUnknownUnknownUnknownNoiOSSmart After CareUhm et al [46]
Clinical and Technological Strengths and Weaknesses
Regarding the studies’ strengths, 2 of them involved the same
app called Pit-a-Pat [42,44]. Pit-a-Pat was developed for cancer
patients to self-report factors related with the diagnosis itself
and the subsequent treatments: (1) sleep-disturbance symptoms,
(2) acute symptoms related to cytotoxic chemotherapeutic
agents, and (3) medication diary for antihormonal treatment.
Kim et al [42] studied the accuracy of a mobile mental health
tracker for depression screening, as well as the adherence on
screening accuracy. For that purpose, daily patient reports of
anxiety symptoms, mood, and sleep satisfaction were collected
through a reliable and valid questionnaire (PHQ-9). The app
involved user-friendly functionalities in the form of a facial
emoticon scale. Min et al [44] studied the patient’s self-reported
sleep disturbance, HRQoL status, and depression symptoms via
the Pit-a-Pat app on a daily basis for 90 days with standardized
questionnaires. Push notifications were sent to participants daily
at 9 AM and 7 PM.
LoseIt! [43] was a Web- and mobile-based app, not cancer
targeted, used for logging food intake and volitional exercise.
McCarroll et al [43] aimed to assess a 4-week comprehensive
lifestyle program with emphasis on nutrition quality, physical
activity, and improving eating self-efficacy delivered using a
beta health care provider version of LoseIt! in which the patients
could log daily food choices, daily exercise type and duration,
and daily body weight over the treatment period. Participants
received motivational patient-provider feedback notifications
(phone call, email message, and/or a push notification) in
response to their individual input in the LoseIt! app.
Interaktor [45] was codesigned by patients and health care
personnel as an interactive app for mobile phones and tablets.
Interaktor was specifically intended for early detection,
reporting, and management of symptoms and concerns during
treatment for prostate cancer. Daily reports via the app enable
instant support from a nurse in early detection and management
of symptoms and concerns in real-time during treatment for
prostate cancer. The app features included symptom assessment,
a risk assessment model for alerts directly to a nurse, continuous
access to evidence-based self-care advice, and links to relevant
websites. The apps sent patients a reminder message if they had
not submitted their report. In addition, the system sent 2 alerts
(yellow and red) to the patients, depending on their symptom
occurrence and frequency. The red meant a higher priority
(should contact the nurse within an hour), and the yellow alert
indicated that the nurse should be called that day. Sundberg et
al [45] included a control and an intervention group in their
study, which used the app for daily, real-time assessment and
management of symptoms and concerns during radiotherapy
treatment. Participants were asked to send reports daily and at
any time point when they felt unwell during the radiation
treatment (5 to 8 weeks) and the following 3 weeks.
Smart After Care [46] was a newly developed mobile phone
exercise app. This app recorded minutes of physical activity
weekly and established a weekly goal for minutes of activity
beginning in the second week. Every week, the achievement
rate was displayed by the app. Also, patients receiving hormonal
therapy could watch a video clip of resistance and stretching
exercises through the app. This study included standardized
QoL questionnaires and a user satisfaction survey in the
intervention group. Patients in the study by Uhm et al [46]
performed a 12-week regimen of aerobic and resistance exercise
through Smart After Care, where the intervention group received
a pedometer and Smart After Care to perform 150 or 90 minutes
of aerobic exercise.
Among the main weaknesses could be cited the small samples
of the studies [42-44] and the lack of RCT protocols and
framework-based apps. Moreover, we can report only 1 app for
free download on the market [43], which was used with breast
cancer patients despite not being cancer-focused.
Patients’ User Experience
Only 1 study [46] reported information regarding patient
satisfaction level, and only 1 app showed a quality certification
[43] and a considerable number of user comments (see Table
4). The mean Likert scale response for overall patient
satisfaction with the service was 4.27/5 in the mHealth group
[46].
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Table 4. Patient satisfaction levels provided by the health literature review and the online store search (n=5).
Number of user comments (OSR)Health certification (OSR)Ratings (OSRa)Patients satisfactionStudy
UnknownUnknownUnknownUnknownKim et al [42]
Android: 61,063; iOS: 374,815Helix’s CLIAb certified and CAPc
accredited lab
Android: 4.4; iOS: 4.0UnknownMcCarroll et al [43]
UnknownUnknownUnknownUnknownMin et al [44]
UnknownUnknownUnknownUnknownSundberg et al [45]
UnknownUnknownUnknownSatisfied with useUhm et al [46]
aOSR: Online store research.
bCLIA: Certified Laboratory Improvement Amendments.
cCAP: College of American Pathologists.
Discussion
Overview
The use of mobile phone apps for health purposes continues to
increase [7], and currently thousands and thousands of health
apps are available on the online market. They target different
health conditions, including cancer. Health apps represent an
opportunity to monitor psychological distress and QoL related
to cancer and its associated treatments. Our systematic review
shows that the scientific literature referring to apps targeting
breast or prostate cancer patients and involving QoL and/or
well-being measurements is very modest, as we only could
identify 5 studies meeting the inclusion criteria. However, the
quality and dates of publication show a current scientific interest
in this research topic.
The most recent reviews involving focused cancer apps started
the searching methodology by looking for apps on the online
stores, followed by searching bibliographic databases of health
literature [8,13]. However, we considered it more appropriate
to start by determining whether rigorous trials had been
published on cancer-focused apps. Hence, we conducted the
systematic literature review first, and then we downloaded the
apps from the market stores to examine them.
More Evidence-Based Apps Are Needed
Despite the increase in the number of health care apps available
[15], only a very few of them discussed in the scientific literature
focus on QoL and/or well-being assessment in breast or prostate
cancer patient even though breast and prostate cancer are the
most prevalent cancers diagnosed [1] and QoL and well-being
are frequently assessed to determine the health status of cancer
patients [2,3]. There are only 2 studies that reported QoL
improvement by using related-treatment health apps [45,46].
Related research on health apps for cancer patients was identified
but not included in the review due to the following reasons (see
Multimedia Appendix 1): it did not involve mobile phone apps
[30-32,35,37,38], it did not assess QoL or well-being
[29,33,34,36,40], or it involved qualitative studies focused on
feasibility or patient opinions [39,41].
We selected the QoL measure considering it has a wide range
of variables involving other psychological measures (eg,
cognitive, emotional, and social abilities) and not only as
performance status and daily functional activities [29], symptom
experience [33], or chemotherapy-related symptoms (nausea,
vomiting, fatigue, mucositis, hand-foot syndrome, and diarrhea)
[34].
We have defined well-being as existing levels of general anxiety
and depression symptoms and not only as perceived stress level
[36] assessed by the Perceived Stress Scale (PSS) [56], a scale
“designed to measure the degree to which situations in one’s
life are appraised as stressful” and suggested by its own authors
“as an outcome measure of experienced levels of stress” [56],
not well-being levels.
In our review, only 1 of the selected papers provided information
regarding patient satisfaction level [46], therefore it is not
possible to draw conclusions about the patient satisfaction or
perceived effectiveness of the current apps.
Most of the apps referred to in the scientific literature targeted
breast cancer, as in previous reviews [8,13,16-18], and only 1
study focused on prostate cancer. All of these health apps were
developed by university institutions; in contrast with the review
of Mobasheri et al [18], which reports that a minority of medical
professionals were involved in the apps. Our results showed
that, a priori, all the studies have been hosted by significant
research and educational institutions.
With regard to the technological characteristics, it should be
noted that the 3 apps specifically designed for cancer patients
[42,44-46] were not available for download on the market.
Furthermore, only 1 [43] out of 4 total apps included was
available for download at the online store, and despite this app
(LoseIt!) not being specifically patient-targeted, it was used by
50 breast cancer patients to manage exercise and nutrition
concerns.
Clinical and Technological Strengths and Weaknesses
Regarding the studies’ strengths, the use of related-treatment
mobile phone apps has resulted in a significant improvement
in cancer patients’ QoL [45,46]. Some features like displaying
daily patient reports in real time and providing personalized
feedback [43,45] have also been pointed out as a significant
advantage of the apps [34]. Moreover, if the assessment involves
user-friendly functionalities such as a facial emoticon scale [42],
which could be adapted to the small phone screen, this may
facilitate user participation, potentially making the data more
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useful. Previous studies [31] have reported important usability
adaptation, incorporating several design decisions to account
for patients with various disabilities (eg, impaired vision),
presenting only 1 question at a time to patients. The easy and
visual (similar to a stock chart) way of obtaining the information
displayed by the app as feedback on the symptoms report form
at any time during the study has also been mentioned as a
relevant strength [29]. Also, it is notable that when some
researchers wished to test a general-population–targeted app
with cancer patients, they delivered a cancer-focused health
care provider beta version [43] and designed the user interface
of the app based on reliable guidelines developed by the National
Cancer Institute, like previous authors did [31].
Participants using their own mobile phones have mentioned this
as better than being provided with an additional device [44],
probably because in the latter case they must deal with 2 mobile
phones in their daily life or because they prefer some relative
freedom for testing the app, meaning the possibility of using
the app at their convenience with no minimum amount of time
to be spent using the app, as previous authors have reported
[41]. In contrast, other studies have pointed out patient
preferences for using a device without phone functionality [57]
instead of using their own phones. Users strongly appreciate
the use of no personal patient identifiers or other information
stored on the devices used [30], as well as pseudonymizing and
data protection [4]. Apps that can be used on more than 1 device
could provide the patients with more possibilities to test them,
such as LoseIt! [43], which offers both website and mobile
versions for users, or Interaktor [45], available for mobile phones
and tablets. The real-time feedback component and the
motivational feedback notification are considered relevant
strengths as well. The flexibility in the self-reporting task [45]
could probably be a more suitable option in oncological settings
than prefixed hours of a day [44] because of the patients’ highly
variable functional status during the day, largely dependent on
the medical treatments.
Among the main weaknesses could be (1) no cancer-focused
apps are being used in studies involving cancer patients
[36,40,41,43,57], (2) many of these studies have small samples,
(3) studies are without rigorous design based on RCTs, (4)
studies are not free to the user, (5) no theoretical framework is
reported, and (6) there are usability and accessibility issues with
cancer patients.
It is important to highlight the relevance of using cancer-focused
apps in oncological settings, as cancer patients could be
considered vulnerable recipients [4]. People suffering from
cancer have to struggle with quick relapses, bad prognoses [4],
side effects caused by cancer treatments, and psychological
distress [2]. Also, they represent a population interested in doing
everything possible to improve their health [4], so they could
be interested in using apps that do not constitute reliable and
accurate tools for them, which is even worse if the patients have
to pay for them. Mobasheri et al [18] reported that of the 30
apps reviewed, which functioned as self-assessment tools for
breast disease, only 2 (2/30, 7%) had a documented evidence
base (the rest relied on empirical data). It is imperative to
develop apps and other health information and technology
systems specifically targeted to cancer patients.
Although some encouraging results have been reported using
apps in cancer patients [34], bigger samples sizes and
framework-based and RCT designs are needed in order to obtain
stronger research conclusions. Otherwise, serious concerns
could arise regarding the lack of validation [12] and quality
control [15] of the studies. Furthermore, the identification of
rigorous trials involving empirical testing of these mobile phone
apps in oncological settings is imperative, as none of the selected
studies in this review followed a randomized method and only
1 was based on a previous framework. The use of theories,
models, and frameworks for apps will help to identify the
mechanisms, approaches, and functionalities that work best.
Cancer patients and survivors could have cognitive deterioration
due to treatments. Therefore, usability and accessibility are
relevant aspects to be considered in the development process
of these apps, especially when they are intended for older people.
Apps not designed for cancer patients and survivors could entail
difficult challenges for them, resulting in reduced adoption and
engagement rates. Equally, the large variety of apps available
makes it difficult to establish which of them are the most
adequate for breast and prostate cancer patients and what is the
best way to use them. Also, patients could become overwhelmed
due to the huge number of cancer apps available [11]. Because
of this, stronger efforts should be made to consolidate the
evidence base, effectiveness, and safety of cancer-focused apps
[8].
In line with previous research [8,13,16-18,20,21], we consider
a main challenge the task of ensuring that those apps that are
planned to be used with cancer patients be effectively
cancer-focused, meaning that they should have been originally
designed for, tested on, and adapted to the cancer population.
Only if this technology is evidence-based and targeted to cancer
patients can health care providers guarantee the apps’ safety,
accuracy, reliability, and high quality and be able to recommend
them in oncological care settings.
Patients’ Satisfaction With the Health Apps
Regarding patients’ satisfaction, it is noteworthy that only 1
app of the 3 reviewed reported a quality certification and showed
user comments regarding its use. Moreover, it is relevant that
this app was not cancer-focused and was the only one available
for download at the online store. Only user-friendly and
quality-certified apps should be provided to cancer patients.
Thus, these health apps must be available for download at
market stores once they are certified as useful tools for cancer
patients. It would probably be helpful as well that these apps
provide new users with comments about other patient’s
experiences, in order to obtain a more powerful overview of the
main features included in the app.
More evidence on the patient satisfaction level using health apps
for QoL and/or well-being assessment in oncological settings
is needed. In our review, only 1 study [46] focusing on cancer
patients provided information about satisfaction level.
People affected by cancer are usually open to strategies that
could have a positive influence on their disease [4]. Probably
due to this fact, mobile phone developers and health care teams
involved in oncological settings should be especially careful
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with the apps that are going to be used and tested by this
population and implement patient-centered design approaches.
Current RCTs are still being developed that might produce
promising data to help reach a high-quality evidence base for
apps for cancer patients’ use [32,57-59].
Limitations
Our study had certain limitations. Our selection criteria
intentionally excluded apps that were not specifically focused
on breast or prostate cancer patients. We considered only the
assessment of 2 main psychological variables in
psycho-oncological care: QoL and well-being (anxiety and
depression symptoms). Additional studies could consider other
psychological measures such as fatigue or the secondary
symptoms produced by the cancer treatments. Although our
data search represents a wide range of peer-reviewed journals,
we might have missed studies that were not identified with our
search terms or that were not published.
Conclusions
Despite the existence of hundreds of studies involving mobile
phone health apps used by cancer patients, there is a lack of
rigorous trials regarding QoL and/or well-being assessment in
breast and/or prostate cancer patients. More evidence-based
apps, which could be tested in future RCT protocols, are still
needed. However, promising results are expected to be available
from some RCTs that are still running. A strong and collective
effort should be made by all health care providers to determine
those cancer-focused apps that provide useful and reliable tools
for cancer patients’ disease management.
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